TITLE

Neoadjuvant Chemotherapy in Stage III Breast Cancer

AUTHOR(S)
Alassas, Mohamed; Quyen Chu; Burton, Gary; Ampil, Fred; Mizell, Jason; Li, Benjamin D.
PUB. DATE
June 2005
SOURCE
American Surgeon;Jun2005, Vol. 71 Issue 6, p487
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Neoadjuvanl chemotherapy in advanced breast cancer can potentially downstage disease prior to definitive surgery. In this study, a doxorubicin-based neoadjuvant regimen was administered to stage III breast cancer patients to assess 1) primary tumor response, 2) tumor involvement of resection margins, and 3) predictive value in cancer outcome. Eighty-two patients with stage IIIA and IIIB breast cancer diagnosed between 1990 and 2003 were studied. All patients received similar chemotherapy regimens, consisting of doxorubicin, cisplatin, and 5-fluorouracil, plus surgery and radiation therapy. End points measured include primary tumor response [complete response (CR) = 100%, partial response (PR) >50%, or no response (NR) ≤50%], resection margins for tumor, disease-free, and overall survival. Kaplan-Meier and log-rank tests were performed. Of the 82 patients studied, 34 received neoadjuvant therapy, 48 received conventional postoperative treatment. Seventy-two per cent of the stage IIIB and 22 per cent of the stage IIIA patients received neoadjuvant therapy. In the neoadjuvant group, 29 (85%) patients demonstrated tumor response, 9 (26%) of which were CR. Tumor-free resection margins were achieved in 94 per cent of the neoadjuvant group. Survival analysis demonstrated no benefit comparing neoadjuvant versus postoperative adjuvant therapy but hints at improved disease-free survival in neoadjuvant CR patients (log-rank test, P = 0.07). Eighty-five per cent of patients with stage III breast cancer treated with neoadjuvant chemotherapy experienced clinical response, with 26 per cent CR, and 97 per cent tumor-free resection margins. CR may portend a better cancer outcome.
ACCESSION #
17342194

 

Related Articles

  • The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial. Al-Batran, S.-E.; Bischoff, J.; von Minckwitz, G.; Atmaca, A.; Kleeberg, U.; Meuthen, I.; Morack, G.; Lerbs, W.; Hecker, D.; Sehouli, J.; Knuth, A.; Jager, E. // British Journal of Cancer;6/5/2006, Vol. 94 Issue 11, p1615 

    This study evaluates the clinical benefit of pegylated liposomal doxorubicin (PLD) in patients with metastatic breast cancer (MBC), previously treated with conventional anthracyclines. Seventy-nine women with MBC previously treated with anthracyclines received PLD 50 mg m−2 every 4 weeks....

  • Treatment - Adjuvant and Neoadjuvant Therapy.  // Current Medical Literature: Breast Cancer;2008, Vol. 20 Issue 1, p21 

    The article presents abstracts on breast cancer treatment which include using adjuvant therapy, where early stage breast cancer patients received tamoxifen, and the safety of neoadjuvant chemotherapy in the treatment of early stage breast cancer.

  • Breast cancer patients on adjuvant chemotherapy report a wide range of problems not identified by health-care staff. Morten Petersen; Mirjam Sprangers; Neil Aaronson; Henning Mouridsen // Breast Cancer Research & Treatment;Jun2007, Vol. 103 Issue 2, p185 

    Abstract Background  Adjuvant chemotherapy for primary breast cancer is associated with significant side effects. The aims of this study were (1) to compare health-related quality of life (HRQL) in patients undergoing adjuvant chemotherapy to patients not on chemotherapy and (2)...

  • Neoadjuvant chemotherapy in patients with locally advanced breast cancer: A pilot-observational study. Dodiya, Hardik G.; Brahmbhatt, Alay P.; Khatri, Priyanka K.; Kaushal, Ashish M.; Vijay, D. G. // Journal of Cancer Research & Therapeutics;Jul-Sep2015, Vol. 11 Issue 3, p612 

    Background: Locally advanced breast cancer (LABC) remains major clinical issue with regard to selection and duration of therapy since many years. Neoadjuvant chemotherapy (NACT) is multimodality program, established to treat LABC. Many research tasks are ongoing to develop specific...

  • Breast Cancer.  // Annals of Internal Medicine;9/21/2004, Vol. 141 Issue 6, p454 

    This article cites a study revealing the effectiveness of dose-dense therapy in improving outcomes in node-positive breast cancer. The standard of care for patients with node-positive breast cancer involves administering a predefined course of adjuvant chemotherapy after primary surgery. This...

  • Molecular subtypes of breast cancer and amplification of topoisomerase IIα: predictive role in dose intensive adjuvant chemotherapy. Hannemann, J.; Kristel, P.; van Tinteren, H.; Bontenbal, M.; van Hoesel, Q. G. C. M.; Smit, W. M.; Nooij, M. A.; Voest, E. E.; van der Wall, E.; Hupperets, P.; de Vries, E. G. E.; Rodenhuis, S.; van de Vijver, M. J. // British Journal of Cancer;11/20/2006, Vol. 95 Issue 10, p1334 

    Benefit from chemotherapy treatment in breast cancer patients is determined by the molecular make-up of the tumour. In a retrospective analysis, we determined the molecular subtypes of breast cancer originally defined by expression microarrays by immunohistochemistry in tumours of patients who...

  • Safety and feasibility of adjuvant chemotherapy with S-1 in Japanese breast cancer patients after primary systemic chemotherapy: a feasibility study. Takashi Shigekawa; Akihiko Osaki; Hiroshi Sekine; Nobuaki Sato; Chizuko Kanbayashi; Hiroshi Sano; Hideki Takeuchi; Shigeto Ueda; Noriko Nakamiya; Ikuko Sugitani; Michiko Sugiyama; Hiroko Shimada; Eiko Hirokawa; Takao Takahashi; Toshiaki Saeki // BMC Cancer;2015, Vol. 15 Issue 1, p1 

    Background: Advanced breast cancer patients have a higher risk of postoperative recurrence than early-stage breast cancer patients. Recurrence is believed to be caused by the increase in micrometases, which were not eradicated by preoperative or postoperative chemotherapy. Therefore, a new...

  • Prevention of febrile neutropenia: use of granulocyte colony-stimulating factors. Kelly, S.; Wheatley, D. // British Journal of Cancer;9/15/2009 Supplement 1, Vol. 101, pS6 

    There is good evidence to suggest that dose intensity is important when considering the effectiveness of adjuvant chemotherapy in patients with breast cancer. However, the development of chemotherapy-induced febrile neutropenia can lead to reduction in dose intensity and other treatment...

  • Changing Paradigms in Breast Cancer Management: Introducing Molecular Genetics into the Treatment Algorithm. RAYHANABAD, JESSICA A.; DIFRONZO, L. ANDREW; HAIGH, PHILLIP I.; ROMERO, LINA // American Surgeon;Oct2008, Vol. 74 Issue 10, p887 

    Advances in molecular genetics aimed at individualizing breast cancer treatment have been validated. We examined the use of gene assays predictive of distant recurrence in breast cancer and their impact on adjuvant treatment. A retrospective chart review of 58 T1/T2, node-negative,...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics